There are 702 resources available
413P - Following planned pre-operative (pre-op) chemo-radiotherapy (CRT) for squamous cell cancer (SCC) of the esophagus (eso), why do some patients not undergo surgery (sx)? A service evaluation from a tertiary care hospital in a Low-Middle Income Country (LMIC
Presenter: Shaleen Kumar
Session: Poster Display session
414P - A study on neoadjuvant chemoradiotherapy: Cross-protocol in a tertiary care centre in India
Presenter: Kavya Pamidi
Session: Poster Display session
415P - Safety and short-term efficacy of neoadjuvant FLOT therapy in patients with resectable locally advanced esophageal squamous cell carcinoma
Presenter: Yuri Yoshinami
Session: Poster Display session
416P - Evolutionary and immune microenvironment dynamics determine response to neoadjuvant treatment of oesophageal adenocarcinoma
Presenter: Melissa Barroux
Session: Poster Display session
418P - A PET/CT image-based deep learning approach for precise survival prognosis and clinical management of treatments in patients with esophageal carcinoma
Presenter: Jian-Hua Liu
Session: Poster Display session
419P - Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Additional analyses from 4-year (y) follow-up (FU) of CheckMate 649
Presenter: Lucjan Wyrwicz
Session: Poster Display session
420P - Q-TWiST analysis of nivolumab + chemotherapy versus chemotherapy as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma (GC/GEJC/EAC) in patients with PD-L1 CPS=1 and CPS=5: 4-year follow-u
Presenter: Daniel Lin
Session: Poster Display session
421P - Maintenance therapy with regorafenib (REGO) versus placebo after first-line (1L) platinum and fluoropyrimidines-based chemotherapy in HER2-negative advanced gastric (GC)/gastroesophageal junction (GEJ) cancer: Results of phase II randomized a-MANTRA study
Presenter: Carmine Pinto
Session: Poster Display session
422P - HLX22 plus HLX02 and XELOX as first-line therapy for HER2-positive advanced gastric/gastroesophageal junction cancer: Updated results from a randomized, double-blind phase II study
Presenter: Jin Li
Session: Poster Display session
423P - Multicentre, multi-cohort, single-arm phase II trial of tremelimumab and durvalumab as neoadjuvant or definitive treatment of patients (pts) with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJ
Presenter: ALESSANDRA RAIMONDI
Session: Poster Display session